BACKGROUND: Acute myeloid leukemia (AML) with t(6;11)(q27;q23) is a well established but rare entity, and few studies have reported the full clinical, hematologic, and outcome data of patients with this disease. METHODS: To characterize the features of t(6;11) AML, the authors searched the Cancer and Leukemia Group B (CALGB) cytogenetic database comprising 2667 adults with newly diagnosed, de novo AML and identified 16 patients (0.6%) with t(6;11). A review of the literature identified 33 adults with de novo t(6;11) AML for whom survival data were available. RESULTS: CALGB patients had a median age of 45 years (range, 22-65 years) and commonly presented with French-American-British (FAB) subtype M4 or M5 (81%). Gingival involvement at presentation was common (31%). All patients with gingival involvement had FAB M4. Compared with other patients with M4 AML in the CALGB database (n = 429), patients with M4 and t(6;11) (n = 7) had a higher frequency of gingival hypertrophy at presentation (71% vs. 17%, P = 0.003). Patients with t(6;11) were more likely to be African American (P = 0.02) and to die during induction (P = 0.03) than those without t(6;11). The complete response (CR) rate was 69% (11 of 16 patients), and CR duration was short (median, 9 months). The estimated probability of 2-year survival was 13%. Both long-term survivors received allogeneic stem cell transplantation. The estimated probability of 2-year survival of patients reported in the literature was 15%. CONCLUSIONS: Although the patient sample was small, the authors suggested that investigational approaches, including allogeneic transplantation, be considered for adults with t(6;11) AML. Copyright 2004 American Cancer Society.
BACKGROUND:Acute myeloid leukemia (AML) with t(6;11)(q27;q23) is a well established but rare entity, and few studies have reported the full clinical, hematologic, and outcome data of patients with this disease. METHODS: To characterize the features of t(6;11) AML, the authors searched the Cancer and Leukemia Group B (CALGB) cytogenetic database comprising 2667 adults with newly diagnosed, de novo AML and identified 16 patients (0.6%) with t(6;11). A review of the literature identified 33 adults with de novo t(6;11) AML for whom survival data were available. RESULTS: CALGB patients had a median age of 45 years (range, 22-65 years) and commonly presented with French-American-British (FAB) subtype M4 or M5 (81%). Gingival involvement at presentation was common (31%). All patients with gingival involvement had FAB M4. Compared with other patients with M4 AML in the CALGB database (n = 429), patients with M4 and t(6;11) (n = 7) had a higher frequency of gingival hypertrophy at presentation (71% vs. 17%, P = 0.003). Patients with t(6;11) were more likely to be African American (P = 0.02) and to die during induction (P = 0.03) than those without t(6;11). The complete response (CR) rate was 69% (11 of 16 patients), and CR duration was short (median, 9 months). The estimated probability of 2-year survival was 13%. Both long-term survivors received allogeneic stem cell transplantation. The estimated probability of 2-year survival of patients reported in the literature was 15%. CONCLUSIONS: Although the patient sample was small, the authors suggested that investigational approaches, including allogeneic transplantation, be considered for adults with t(6;11) AML. Copyright 2004 American Cancer Society.
Authors: A Pigneux; M Labopin; J Maertens; C Cordonnier; L Volin; G Socié; D Blaise; C Craddock; N Milpied; U Bacher; F Malard; J Esteve; A Nagler; M Mohty Journal: Leukemia Date: 2015-06-17 Impact factor: 11.528
Authors: Marius Bill; Krzysztof Mrózek; Jessica Kohlschmidt; Ann-Kathrin Eisfeld; Christopher J Walker; Deedra Nicolet; Dimitrios Papaioannou; James S Blachly; Shelley Orwick; Andrew J Carroll; Jonathan E Kolitz; Bayard L Powell; Richard M Stone; Albert de la Chapelle; John C Byrd; Clara D Bloomfield Journal: Proc Natl Acad Sci U S A Date: 2020-10-05 Impact factor: 11.205
Authors: Y Chen; H Kantarjian; S Pierce; S Faderl; S O'Brien; W Qiao; L Abruzzo; M de Lima; P Kebriaei; E Jabbour; N Daver; T Kadia; Z Estrov; G Garcia-Manero; J Cortes; F Ravandi Journal: Leukemia Date: 2012-11-08 Impact factor: 11.528
Authors: Brian V Balgobind; Susana C Raimondi; Jochen Harbott; Martin Zimmermann; Todd A Alonzo; Anne Auvrignon; H Berna Beverloo; Myron Chang; Ursula Creutzig; Michael N Dworzak; Erik Forestier; Brenda Gibson; Henrik Hasle; Christine J Harrison; Nyla A Heerema; Gertjan J L Kaspers; Anna Leszl; Nathalia Litvinko; Luca Lo Nigro; Akira Morimoto; Christine Perot; Rob Pieters; Dirk Reinhardt; Jeffrey E Rubnitz; Franklin O Smith; Jan Stary; Irina Stasevich; Sabine Strehl; Takashi Taga; Daisuke Tomizawa; David Webb; Zuzana Zemanova; C Michel Zwaan; Marry M van den Heuvel-Eibrink Journal: Blood Date: 2009-06-15 Impact factor: 22.113
Authors: Jackson Orem; Edward Katongole Mbidde; Bo Lambert; Silvia de Sanjose; Elisabete Weiderpass Journal: Afr Health Sci Date: 2007-09 Impact factor: 0.927